{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T19:44:43Z","timestamp":1787773483889,"version":"build-2784847793"},"reference-count":90,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2017,3,1]],"date-time":"2017-03-01T00:00:00Z","timestamp":1488326400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,10,4]],"date-time":"2016-10-04T00:00:00Z","timestamp":1475539200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","cell.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","bmn.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Trends in Parasitology"],"published-print":{"date-parts":[[2017,3]]},"DOI":"10.1016\/j.pt.2016.09.004","type":"journal-article","created":{"date-parts":[[2016,10,11]],"date-time":"2016-10-11T03:30:08Z","timestamp":1476156608000},"page":"175-184","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":30,"title":["Mathematical Modelling to Guide Drug Development for Malaria Elimination"],"prefix":"10.1016","volume":"33","author":[{"given":"Hannah C.","family":"Slater","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucy C.","family":"Okell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Azra C.","family":"Ghani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.pt.2016.09.004_bib0005","series-title":"World Malaria Report 2015","year":"2015"},{"key":"10.1016\/j.pt.2016.09.004_bib0455","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1038\/nature15535","article-title":"The effect of malaria control on Plasmodium falciparum in Africa between 2000 and 2015","volume":"526","author":"Bhatt","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.pt.2016.09.004_bib0460","doi-asserted-by":"crossref","first-page":"1592","DOI":"10.1016\/S0140-6736(10)61269-X","article-title":"Operational strategies to achieve and maintain malaria elimination","volume":"376","author":"Moonen","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.pt.2016.09.004_bib0465","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/S1473-3099(15)00487-9","article-title":"Dihydroartemisinin-piperaquine resistance in Plasmodium falciparum malaria in Cambodia: a multisite prospective cohort study","volume":"16","author":"Amaratunga","year":"2016","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.pt.2016.09.004_bib0470","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1111\/j.1365-3156.2006.01690.x","article-title":"Surveillance of the efficacy of artesunate and mefloquine combination for the treatment of uncomplicated falciparum malaria in Cambodia","volume":"11","author":"Denis","year":"2006","journal-title":"Trop. Med. Int. Health"},{"key":"10.1016\/j.pt.2016.09.004_bib0475","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1056\/NEJMoa0808859","article-title":"Artemisinin resistance in Plasmodium falciparum malaria","volume":"361","author":"Dondorp","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.pt.2016.09.004_bib0480","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1038\/clpt.2009.51","article-title":"The global portfolio of new antimalarial medicines under development","volume":"85","author":"Olliaro","year":"2009","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.pt.2016.09.004_bib0485","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1038\/nrd2972","article-title":"New medicines to improve control and contribute to the eradication of malaria","volume":"8","author":"Wells","year":"2009","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.pt.2016.09.004_bib0490","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1038\/nrd4573","article-title":"Malaria medicines: a glass half full?","volume":"14","author":"Wells","year":"2015","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.pt.2016.09.004_bib0495","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1111\/bcp.12288","article-title":"Modelling the time course of antimalarial parasite killing: a tour of animal and human models, translation and challenges","volume":"79","author":"Patel","year":"2015","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.pt.2016.09.004_bib0500","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1186\/1475-2875-13-62","article-title":"Pharmacological considerations in the design of anti-malarial drug combination therapies \u2013 is matching half-lives enough?","volume":"13","author":"Hastings","year":"2014","journal-title":"Malaria J."},{"key":"10.1016\/j.pt.2016.09.004_bib0505","doi-asserted-by":"crossref","first-page":"3414","DOI":"10.1128\/AAC.44.12.3414-3424.2000","article-title":"Mefloquine pharmacokinetic-pharmacodynamic models: implications for dosing and resistance","volume":"44","author":"Simpson","year":"2000","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.pt.2016.09.004_bib0510","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1038\/clpt.2011.254","article-title":"Population pharmacokinetics and pharmacodynamics of piperaquine in children with uncomplicated falciparum malaria","volume":"91","author":"Tarning","year":"2012","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.pt.2016.09.004_bib0515","doi-asserted-by":"crossref","first-page":"e1001564","DOI":"10.1371\/journal.pmed.1001564","article-title":"The effect of dosing regimens on the antimalarial efficacy of dihydroartemisinin-piperaquine: a pooled analysis of individual patient data","volume":"10","year":"2013","journal-title":"PLoS Med."},{"key":"10.1016\/j.pt.2016.09.004_bib0520","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1208\/s12248-014-9647-y","article-title":"Making the most of clinical data: reviewing the role of pharmacokinetic-pharmacodynamic models of anti-malarial drugs","volume":"16","author":"Simpson","year":"2014","journal-title":"AAPS J."},{"key":"10.1016\/j.pt.2016.09.004_bib0525","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1186\/1475-2875-13-138","article-title":"Optimizing the programmatic deployment of the anti-malarials artemether-lumefantrine and dihydroartemisinin-piperaquine using pharmacological modelling","volume":"13","author":"Hodel","year":"2014","journal-title":"Malaria J."},{"key":"10.1016\/j.pt.2016.09.004_bib0530","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1017\/S0031182001008952","article-title":"Mathematical modelling of malaria chemotherapy: combining artesunate and mefloquine","volume":"124","author":"Hoshen","year":"2002","journal-title":"Parasitology"},{"key":"10.1016\/j.pt.2016.09.004_bib0535","doi-asserted-by":"crossref","first-page":"e1003151","DOI":"10.1371\/journal.pcbi.1003151","article-title":"Improving pharmacokinetic-pharmacodynamic modeling to investigate anti-infective chemotherapy with application to the current generation of antimalarial drugs","volume":"9","author":"Kay","year":"2013","journal-title":"PLoS Comput. Biol."},{"key":"10.1016\/j.pt.2016.09.004_bib0540","doi-asserted-by":"crossref","first-page":"2155","DOI":"10.1093\/jac\/dku120","article-title":"Predicting the parasite killing effect of artemisinin combination therapy in a murine malaria model","volume":"69","author":"Patel","year":"2014","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.pt.2016.09.004_bib0545","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1128\/AAC.48.4.1329-1334.2004","article-title":"Activities of artesunate and primaquine against asexual- and sexual-stage parasites in falciparum malaria","volume":"48","author":"Pukrittayakamee","year":"2004","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.pt.2016.09.004_bib0550","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1128\/CMR.00051-10","article-title":"Epidemiology and infectivity of Plasmodium falciparum and Plasmodium vivax gametocytes in relation to malaria control and elimination","volume":"24","author":"Bousema","year":"2011","journal-title":"Clin. Microbiol. Rev."},{"key":"10.1016\/j.pt.2016.09.004_bib0555","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1186\/1475-2875-9-136","article-title":"Revisiting the circulation time of Plasmodium falciparum gametocytes: molecular detection methods to estimate the duration of gametocyte carriage and the effect of gametocytocidal drugs","volume":"9","author":"Bousema","year":"2010","journal-title":"Malaria J."},{"key":"10.1016\/j.pt.2016.09.004_bib0560","doi-asserted-by":"crossref","first-page":"e1003434","DOI":"10.1371\/journal.pcbi.1003434","article-title":"Modeling within-host effects of drugs on Plasmodium falciparum transmission and prospects for malaria elimination","volume":"10","author":"Johnston","year":"2014","journal-title":"PLoS Comput. Biol."},{"key":"10.1016\/j.pt.2016.09.004_bib0565","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1186\/s12916-016-0621-7","article-title":"Gametocyte carriage in uncomplicated Plasmodium falciparum malaria following treatment with artemisinin combination therapy: a systematic review and meta-analysis of individual patient data","volume":"14","author":"Group","year":"2016","journal-title":"BMC Med."},{"key":"10.1016\/j.pt.2016.09.004_bib0570","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1186\/1475-2875-7-125","article-title":"Reduction of transmission from malaria patients by artemisinin combination therapies: a pooled analysis of six randomized trials","volume":"7","author":"Okell","year":"2008","journal-title":"Malaria J."},{"key":"10.1016\/j.pt.2016.09.004_bib0575","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1186\/s12916-016-0581-y","article-title":"Single low dose primaquine to reduce gametocyte carriage and Plasmodium falciparum transmission after artemether-lumefantrine in children with asymptomatic infection: a randomised, double-blind, placebo-controlled trial","volume":"14","author":"Goncalves","year":"2016","journal-title":"BMC Med."},{"key":"10.1016\/j.pt.2016.09.004_bib0580","first-page":"CD008152","article-title":"Primaquine or other 8-aminoquinoline for reducing Plasmodium falciparum transmission","volume":"2","author":"Graves","year":"2015","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.pt.2016.09.004_bib0585","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/S1473-3099(12)70198-6","article-title":"Primaquine to prevent transmission of falciparum malaria","volume":"13","author":"White","year":"2013","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.pt.2016.09.004_bib0590","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1186\/s12936-016-1163-3","article-title":"Transmission-blocking strategies: the roadmap from laboratory bench to the community","volume":"15","author":"Goncalves","year":"2016","journal-title":"Malaria J."},{"key":"10.1016\/j.pt.2016.09.004_bib0595","doi-asserted-by":"crossref","first-page":"e1000402","DOI":"10.1371\/journal.pmed.1000402","article-title":"A research agenda for malaria eradication: drugs","volume":"8","year":"2011","journal-title":"PLoS Med."},{"key":"10.1016\/j.pt.2016.09.004_bib0600","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1128\/AAC.03942-14","article-title":"Lead clinical and preclinical antimalarial drugs can significantly reduce sporozoite transmission to vertebrate populations","volume":"59","author":"Upton","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.pt.2016.09.004_bib0605","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1038\/ncomms2241","article-title":"Factors determining the occurrence of submicroscopic malaria infections and their relevance for control","volume":"3","author":"Okell","year":"2012","journal-title":"Nat. Commun."},{"key":"10.1016\/j.pt.2016.09.004_bib0610","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1086\/644781","article-title":"Submicroscopic infection in Plasmodium falciparum-endemic populations: a systematic review and meta-analysis","volume":"200","author":"Okell","year":"2009","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.pt.2016.09.004_bib0615","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.pt.2014.02.004","article-title":"The role of submicroscopic parasitemia in malaria transmission: what is the evidence?","volume":"30","author":"Lin","year":"2014","journal-title":"Trends Parasitol."},{"key":"10.1016\/j.pt.2016.09.004_bib0620","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.pt.2015.04.004","article-title":"Assessing the infectious reservoir of falciparum malaria: past and future","volume":"31","author":"Stone","year":"2015","journal-title":"Trends Parasitol."},{"key":"10.1016\/j.pt.2016.09.004_bib0625","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1186\/s12879-015-0887-y","article-title":"Mass campaigns with antimalarial drugs: a modelling comparison of artemether-lumefantrine and DHA-piperaquine with and without primaquine as tools for malaria control and elimination","volume":"15","author":"Gerardin","year":"2015","journal-title":"BMC Infect. Dis."},{"key":"10.1016\/j.pt.2016.09.004_bib0630","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1186\/1475-2875-13-380","article-title":"The diminishing returns of atovaquone-proguanil for elimination of Plasmodium falciparum malaria: modelling mass drug administration and treatment","volume":"13","author":"Maude","year":"2014","journal-title":"Malaria J."},{"key":"10.1016\/j.pt.2016.09.004_bib0635","doi-asserted-by":"crossref","first-page":"e20179","DOI":"10.1371\/journal.pone.0020179","article-title":"The potential contribution of mass treatment to the control of Plasmodium falciparum malaria","volume":"6","author":"Okell","year":"2011","journal-title":"PLoS ONE"},{"key":"10.1016\/j.pt.2016.09.004_bib0640","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1186\/s12936-016-1202-0","article-title":"Operational strategies of anti-malarial drug campaigns for malaria elimination in Zambia's southern province: a simulation study","volume":"15","author":"Stuckey","year":"2016","journal-title":"Malaria J."},{"key":"10.1016\/j.pt.2016.09.004_bib0645","doi-asserted-by":"crossref","first-page":"e226","DOI":"10.1371\/journal.pmed.0050226","article-title":"Modelling the impact of artemisinin combination therapy and long-acting treatments on malaria transmission intensity","volume":"5","author":"Okell","year":"2008","journal-title":"PLoS Med."},{"key":"10.1016\/j.pt.2016.09.004_bib0650","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1016\/S1473-3099(15)00550-2","article-title":"Primaquine to stop transmission of falciparum malaria","volume":"16","author":"Greenwood","year":"2016","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.pt.2016.09.004_bib0655","doi-asserted-by":"crossref","first-page":"1972","DOI":"10.1093\/infdis\/jiu351","article-title":"The potential impact of adding ivermectin to a mass treatment intervention to reduce malaria transmission: a modelling study","volume":"210","author":"Slater","year":"2014","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.pt.2016.09.004_bib0660","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1186\/s12936-015-0691-6","article-title":"Establishment of the Ivermectin Research for Malaria Elimination Network: updating the research agenda","volume":"14","author":"Chaccour","year":"2015","journal-title":"Malaria J."},{"key":"10.1016\/j.pt.2016.09.004_bib0665","doi-asserted-by":"crossref","first-page":"e18947","DOI":"10.1371\/journal.pone.0018947","article-title":"Modelling the protective efficacy of alternative delivery schedules for intermittent preventive treatment of malaria in infants and children","volume":"6","author":"Cairns","year":"2011","journal-title":"PLoS ONE"},{"key":"10.1016\/j.pt.2016.09.004_bib0670","doi-asserted-by":"crossref","first-page":"555","DOI":"10.4269\/ajtmh.14-0490","article-title":"Comparing the impact of artemisinin-based combination therapies on malaria transmission in sub-Saharan Africa","volume":"92","author":"Ndeffo Mbah","year":"2015","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"10.1016\/j.pt.2016.09.004_bib0675","doi-asserted-by":"crossref","first-page":"5606","DOI":"10.1038\/ncomms6606","article-title":"Contrasting benefits of different artemisinin combination therapies as first-line malaria treatments using model-based cost-effectiveness analysis","volume":"5","author":"Okell","year":"2014","journal-title":"Nat. Commun."},{"key":"10.1016\/j.pt.2016.09.004_bib0680","doi-asserted-by":"crossref","first-page":"921715","DOI":"10.1155\/2012\/921715","article-title":"Modeling the effects of relapse in the transmission dynamics of malaria parasites","volume":"2012","author":"Aguas","year":"2012","journal-title":"J. Parasitol. Res."},{"key":"10.1016\/j.pt.2016.09.004_bib0685","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.jtbi.2012.08.024","article-title":"Modeling Plasmodium vivax: relapses, treatment, seasonality, and G6PD deficiency","volume":"316","author":"Chamchod","year":"2013","journal-title":"J. Theor. Biol."},{"key":"10.1016\/j.pt.2016.09.004_bib0690","doi-asserted-by":"crossref","first-page":"e1979","DOI":"10.1371\/journal.pntd.0001979","article-title":"The potential elimination of Plasmodium vivax malaria by relapse treatment: insights from a transmission model and surveillance data from NW India","volume":"7","author":"Roy","year":"2013","journal-title":"PLoS Negl. Trop. Dis."},{"key":"10.1016\/j.pt.2016.09.004_bib0695","doi-asserted-by":"crossref","first-page":"e04692","DOI":"10.7554\/eLife.04692","article-title":"Modelling the contribution of the hypnozoite reservoir to Plasmodium vivax transmission","volume":"3","author":"White","year":"2014","journal-title":"Elife"},{"issue":"Suppl. 3","key":"10.1016\/j.pt.2016.09.004_bib0700","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1186\/1475-2875-9-S3-S2","article-title":"Anti-malarial drugs and the prevention of malaria in the population of malaria endemic areas","volume":"9","author":"Greenwood","year":"2010","journal-title":"Malaria J."},{"key":"10.1016\/j.pt.2016.09.004_bib0705","doi-asserted-by":"crossref","first-page":"e6627","DOI":"10.1371\/journal.pone.0006627","article-title":"The impact of IPTi and IPTc interventions on malaria clinical burden \u2013 in silico perspectives","volume":"4","author":"Aguas","year":"2009","journal-title":"PLoS ONE"},{"key":"10.1016\/j.pt.2016.09.004_bib0710","doi-asserted-by":"crossref","first-page":"e4383","DOI":"10.1371\/journal.pone.0004383","article-title":"Loss of population levels of immunity to malaria as a result of exposure-reducing interventions: consequences for interpretation of disease trends","volume":"4","author":"Ghani","year":"2009","journal-title":"PLoS ONE"},{"key":"10.1016\/j.pt.2016.09.004_bib0715","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1186\/s12936-015-0805-1","article-title":"Age-shifting in malaria incidence as a result of induced immunological deficit: a simulation study","volume":"14","author":"Pemberton-Ross","year":"2015","journal-title":"Malaria J."},{"key":"10.1016\/j.pt.2016.09.004_bib0720","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/S1473-3099(07)70024-5","article-title":"Reducing the burden of malaria in pregnancy by preventive strategies","volume":"7","author":"Menendez","year":"2007","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.pt.2016.09.004_bib0725","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1038\/ncomms2605","article-title":"A model of parity-dependent immunity to placental malaria","volume":"4","author":"Walker","year":"2013","journal-title":"Nat. Commun."},{"key":"10.1016\/j.pt.2016.09.004_bib0730","doi-asserted-by":"crossref","first-page":"e460","DOI":"10.1016\/S2214-109X(14)70256-6","article-title":"Estimated risk of placental infection and low birthweight attributable to Plasmodium falciparum malaria in Africa in 2010: a modelling study","volume":"2","author":"Walker","year":"2014","journal-title":"Lancet Glob. Health"},{"key":"10.1016\/j.pt.2016.09.004_bib0735","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1016\/S1473-3099(15)00547-2","article-title":"Safety of artemisinins in first trimester of prospectively followed pregnancies: an observational study","volume":"16","author":"Moore","year":"2016","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.pt.2016.09.004_bib0740","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/S1383-5769(02)00084-3","article-title":"A mathematical model for the transmission of Plasmodium vivax malaria","volume":"52","author":"Ishikawa","year":"2003","journal-title":"Parasitol. Int."},{"key":"10.1016\/j.pt.2016.09.004_bib0745","doi-asserted-by":"crossref","first-page":"e1001891","DOI":"10.1371\/journal.pmed.1001891","article-title":"Strategies for understanding and reducing the Plasmodium vivax and Plasmodium ovale hypnozoite reservoir in Papua New Guinean children: a randomised placebo-controlled trial and mathematical model","volume":"12","author":"Robinson","year":"2015","journal-title":"PLoS Med."},{"key":"10.1016\/j.pt.2016.09.004_bib0750","doi-asserted-by":"crossref","first-page":"e0004582","DOI":"10.1371\/journal.pntd.0004582","article-title":"The incidence and differential seasonal patterns of Plasmodium vivax primary infections and relapses in a cohort of children in Papua New Guinea","volume":"10","author":"Ross","year":"2016","journal-title":"PLoS Negl. Trop. Dis."},{"key":"10.1016\/j.pt.2016.09.004_bib0755","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1016\/S1473-3099(15)70124-6","article-title":"Malaria morbidity and mortality in Ebola-affected countries caused by decreased health-care capacity, and the potential effect of mitigation strategies: a modelling analysis","volume":"15","author":"Walker","year":"2015","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.pt.2016.09.004_bib0760","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/S1473-3099(15)00465-X","article-title":"Preventive malaria treatment for contacts of patients with Ebola virus disease in the context of the west Africa 2014-15 Ebola virus disease response: an economic analysis","volume":"16","author":"Carias","year":"2016","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.pt.2016.09.004_bib0765","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1186\/1475-2875-11-292","article-title":"A framework for assessing the risk of resistance for anti-malarials in development","volume":"11","author":"Ding","year":"2012","journal-title":"Malaria J."},{"key":"10.1016\/j.pt.2016.09.004_bib0770","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1186\/1475-2875-9-217","article-title":"Prospective strategies to delay the evolution of anti-malarial drug resistance: weighing the uncertainty","volume":"9","author":"Smith","year":"2010","journal-title":"Malaria J."},{"key":"10.1016\/j.pt.2016.09.004_bib0775","doi-asserted-by":"crossref","first-page":"2116","DOI":"10.1128\/AAC.48.6.2116-2123.2004","article-title":"Evolution of resistance to sulfadoxine-pyrimethamine in Plasmodium falciparum","volume":"48","author":"Gatton","year":"2004","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.pt.2016.09.004_bib0780","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1098\/rstb.2001.1036","article-title":"The evolution of drug-resistant malaria: the role of drug elimination half-life","volume":"357","author":"Hastings","year":"2002","journal-title":"Philos. Trans. R. Soc. Lond. B Biol. Sci."},{"key":"10.1016\/j.pt.2016.09.004_bib0785","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1186\/s12936-015-0810-4","article-title":"Measuring windows of selection for anti-malarial drug treatments","volume":"14","author":"Kay","year":"2015","journal-title":"Malaria J."},{"key":"10.1016\/j.pt.2016.09.004_bib0790","doi-asserted-by":"crossref","first-page":"e141","DOI":"10.1371\/journal.pmed.0030141","article-title":"Potential impact of intermittent preventive treatment (IPT) on spread of drug-resistant malaria","volume":"3","author":"O\u2019Meara","year":"2006","journal-title":"PLoS Med."},{"key":"10.1016\/j.pt.2016.09.004_bib0795","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1186\/1475-2875-7-229","article-title":"Spread of anti-malarial drug resistance: mathematical model with implications for ACT drug policies","volume":"7","author":"Pongtavornpinyo","year":"2008","journal-title":"Malaria J."},{"key":"10.1016\/j.pt.2016.09.004_bib0800","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/S0169-4758(97)01124-1","article-title":"The efficacy of antifolate antimalarial combinations in Africa: a predictive model based on pharmacodynamic and pharmacokinetic analyses","volume":"13","author":"Watkins","year":"1997","journal-title":"Parasitol. Today"},{"key":"10.1016\/j.pt.2016.09.004_bib0805","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1186\/1475-2875-11-303","article-title":"Assessing the utility of an anti-malarial pharmacokinetic-pharmacodynamic model for aiding drug clinical development","volume":"11","author":"Zaloumis","year":"2012","journal-title":"Malaria J."},{"key":"10.1016\/j.pt.2016.09.004_bib0810","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1186\/1475-2875-8-253","article-title":"Hyperparasitaemia and low dosing are an important source of anti-malarial drug resistance","volume":"8","author":"White","year":"2009","journal-title":"Malaria J."},{"key":"10.1016\/j.pt.2016.09.004_bib0815","doi-asserted-by":"crossref","first-page":"4400","DOI":"10.1073\/pnas.1015762108","article-title":"Synthetic ozonide drug candidate OZ439 offers new hope for a single-dose cure of uncomplicated malaria","volume":"108","author":"Charman","year":"2011","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.pt.2016.09.004_bib0820","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.pt.2007.11.008","article-title":"Antimalarial dosing regimens and drug resistance","volume":"24","author":"Barnes","year":"2008","journal-title":"Trends Parasitol."},{"key":"10.1016\/j.pt.2016.09.004_bib0825","doi-asserted-by":"crossref","first-page":"6419","DOI":"10.1128\/AAC.00482-15","article-title":"Altering antimalarial drug regimens may dramatically enhance and restore drug effectiveness","volume":"59","author":"Kay","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.pt.2016.09.004_bib0830","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1016\/j.pt.2004.08.006","article-title":"The origins of antimalarial drug resistance","volume":"20","author":"Hastings","year":"2004","journal-title":"Trends Parasitol."},{"key":"10.1016\/j.pt.2016.09.004_bib0835","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1073\/pnas.1006113108","article-title":"Intrahost modeling of artemisinin resistance in Plasmodium falciparum","volume":"108","author":"Saralamba","year":"2011","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.pt.2016.09.004_bib0840","doi-asserted-by":"crossref","first-page":"e1004689","DOI":"10.1371\/journal.pcbi.1004689","article-title":"Does high-dose antimicrobial chemotherapy prevent the evolution of resistance?","volume":"12","author":"Day","year":"2016","journal-title":"PLoS Comput. Biol."},{"key":"10.1016\/j.pt.2016.09.004_bib0845","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1098\/rstb.1999.0426","article-title":"Antimalarial drug resistance and combination chemotherapy","volume":"354","author":"White","year":"1999","journal-title":"Philos. Trans. R. Soc. Lond. B Biol. Sci."},{"key":"10.1016\/j.pt.2016.09.004_bib0850","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.pt.2010.10.003","article-title":"Why we should effectively treat malaria","volume":"27","author":"Hastings","year":"2011","journal-title":"Trends Parasitol."},{"key":"10.1016\/j.pt.2016.09.004_bib0855","doi-asserted-by":"crossref","first-page":"833","DOI":"10.4269\/ajtmh.14-0031","article-title":"Polymorphisms in Plasmodium falciparum chloroquine resistance transporter and multidrug resistance 1 genes: parasite risk factors that affect treatment outcomes for P. falciparum malaria after artemether-lumefantrine and artesunate-amodiaquine","volume":"91","author":"Venkatesan","year":"2014","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"10.1016\/j.pt.2016.09.004_bib0860","doi-asserted-by":"crossref","first-page":"4719","DOI":"10.1128\/AAC.00835-15","article-title":"Evidence of Plasmodium falciparum malaria multidrug resistance to artemisinin and piperaquine in Western Cambodia: dihydroartemisinin-piperaquine open-label multicenter clinical assessment","volume":"59","author":"Leang","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.pt.2016.09.004_bib0865","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1186\/1475-2875-11-422","article-title":"Policy options for deploying anti-malarial drugs in endemic countries: a population genetics approach","volume":"11","author":"Antao","year":"2012","journal-title":"Malaria J."},{"key":"10.1016\/j.pt.2016.09.004_bib0870","doi-asserted-by":"crossref","first-page":"14216","DOI":"10.1073\/pnas.0804628105","article-title":"Benefits of using multiple first-line therapies against malaria","volume":"105","author":"Boni","year":"2008","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.pt.2016.09.004_bib0875","doi-asserted-by":"crossref","first-page":"e758","DOI":"10.1016\/S2214-109X(15)00162-X","article-title":"Optimum population-level use of artemisinin combination therapies: a modelling study","volume":"3","author":"Nguyen","year":"2015","journal-title":"Lancet Glob. Health"},{"key":"10.1016\/j.pt.2016.09.004_bib0880","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1186\/1475-2875-11-360","article-title":"Rationale for short course primaquine in Africa to interrupt malaria transmission","volume":"11","author":"Eziefula","year":"2012","journal-title":"Malaria J."},{"key":"10.1016\/j.pt.2016.09.004_bib0885","doi-asserted-by":"crossref","first-page":"3136","DOI":"10.1038\/ncomms4136","article-title":"Estimates of the changing age-burden of Plasmodium falciparum malaria disease in sub-Saharan Africa","volume":"5","author":"Griffin","year":"2014","journal-title":"Nat. Commun."},{"key":"10.1016\/j.pt.2016.09.004_bib0890","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1186\/s12936-015-0839-4","article-title":"Seasonality in malaria transmission: implications for case-management with long-acting artemisinin combination therapy in sub-Saharan Africa","volume":"14","author":"Cairns","year":"2015","journal-title":"Malaria J."},{"key":"10.1016\/j.pt.2016.09.004_bib0895","doi-asserted-by":"crossref","first-page":"e18391","DOI":"10.1371\/journal.pone.0018391","article-title":"Determinants of the cost-effectiveness of intermittent preventive treatment for malaria in infants and children","volume":"6","author":"Ross","year":"2011","journal-title":"PLoS ONE"}],"container-title":["Trends in Parasitology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S147149221630160X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S147149221630160X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,7]],"date-time":"2018-09-07T15:25:30Z","timestamp":1536333930000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S147149221630160X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,3]]},"references-count":90,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2017,3]]}},"alternative-id":["S147149221630160X"],"URL":"https:\/\/doi.org\/10.1016\/j.pt.2016.09.004","relation":{},"ISSN":["1471-4922"],"issn-type":[{"value":"1471-4922","type":"print"}],"subject":[],"published":{"date-parts":[[2017,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Mathematical Modelling to Guide Drug Development for Malaria Elimination","name":"articletitle","label":"Article Title"},{"value":"Trends in Parasitology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pt.2016.09.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}